Pfizer In-Licenses Voyager Therapeutics' AAV Capsid for Rare Neurologic Disease Target
Shots:
- Pfizer has exercised one of two options to license a novel capsid produced by Voyager’s TRACERTM capsid discovery platform to support a possible gene therapy program against an unidentified target for a rare neurologic condition
- Voyager will receive $10M in option exercise fees, ~$115M in development, regulatory & commercialization milestones, ~$175M in sales milestones along with royalties
- Voyager holds global rights to all licensed capsids for use with other transgenes & to all other applications of its TRACER technology. Under the 2021 license option agreement for 2 options targeting CNS & CV diseases, Voyager received $30M up front, $20M in exercise fees & ~$580M in milestones along with royalties
Ref: Pfizer | Image: Pfizer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
